Benchmark raised the firm’s price target on Halozyme (HALO) to $90 from $75 and keeps a Buy rating on the shares following what the firm describes as “strong quarterly results and positive forward guidance.”
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HALO:
- Halozyme price target raised to $75 from $65 at Wells Fargo
- Halozyme Earnings Call Highlights Royalty-Fueled Growth
- Halozyme: Strong Royalty Momentum and Underappreciated Multi‑Year Earnings Power Support Buy Rating
- Halozyme reaffirms FY26 non-GAAP EPS view $7.75-$8.25, consensus $8.18
- Halozyme reports Q4 EPS 24c vs. $1.26 last year